Lipid disorders - Justification of methods and goals of treatment

被引:13
作者
Braunstein, JB
Cheng, A
Cohn, G
Aggarwal, M
Nass, CM
Blumenthal, RS
机构
[1] Johns Hopkins Univ Hosp, Ciccarone Ctr Prevent Heart Dis, Div Cardiol, Dept Internal Med, Baltimore, MD 21287 USA
[2] Cleveland Clin Florida, Dept Internal Med, Ft Lauderdale, FL USA
[3] Tufts Univ New England Med Ctr, Dept Internal Med, Boston, MA 02111 USA
关键词
cardiovascular risk factors; coronary heart disease; dyslipidemia; hypercholesterolemia; lipid-lowering agents; statins;
D O I
10.1378/chest.120.3.979
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Dyslipidemia is a major risk factor for coronary heart disease (CHD). While some uncertainty exists about the clinical significance of improving high-density lipoprotein cholesterol and triglyceride levels, large primary- and secondary-prevention studies aimed at lowering low-density lipoprotein cholesterol levels with statins have convincingly reduced CHD events and total mortality. Despite the strong clinical evidence and widely publicized treatment guidelines, many hyperlipidemic patients receive inadequate lipid-lowering treatment. This failure to achieve clinical treatment goals may be due to poor physician adherence to treatment guidelines, patient noncompliance, and the presence of concomitant medical conditions that modify typical hyperlipidemia management. This review considers the challenges and available strategies to optimize lipid management in patients at risk for CHD.
引用
收藏
页码:979 / 988
页数:10
相关论文
共 60 条
  • [1] *AM DIAB ASS, 1999, DIABETES CARE S1, V22, pS56
  • [2] *AM HEART ASS, 1998, 1999 HEART STROK STA
  • [3] DISCONTINUATION OF ANTIHYPERLIPIDEMIC DRUGS - DO RATES REPORTED IN CLINICAL-TRIALS REFLECT RATES IN PRIMARY-CARE SETTINGS
    ANDRADE, SE
    WALKER, AM
    GOTTLIEB, LK
    HOLLENBERG, NK
    TESTA, MA
    SAPERIA, GM
    PLATT, R
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (17) : 1125 - 1131
  • [4] An evidence-based assessment of the NCEP Adult Treatment Panel II guidelines
    Ansell, BJ
    Watson, KE
    Fogelman, AM
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21): : 2051 - 2057
  • [5] RELATION OF HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL AND TRIGLYCERIDES TO INCIDENCE OF ATHEROSCLEROTIC CORONARY-ARTERY DISEASE (THE PROCAM EXPERIENCE)
    ASSMANN, G
    SCHULTE, H
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1992, 70 (07) : 733 - 737
  • [6] Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty
    Bertrand, ME
    McFadden, EP
    Fruchart, JC
    VanBelle, E
    Commeau, P
    Grollier, G
    Bassand, JP
    Machecourt, J
    Cassagnes, J
    Mossard, JM
    Vacheron, A
    Castaigne, A
    Danchin, N
    Lablanche, JM
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1997, 30 (04) : 863 - 869
  • [7] Beyond the Null hypothesis - Do the HERS results disprove the estrogen/coronary heart disease hypothesis?
    Blumenthal, RS
    Zacur, HA
    Reis, SE
    Post, WS
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2000, 85 (08) : 1015 - +
  • [8] Medical therapy versus coronary angioplasty in stable coronary artery disease: A critical review of the literature
    Blumenthal, RS
    Cohn, G
    Schulman, SP
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (03) : 668 - 673
  • [9] Systematic review on the risk and benefit of different cholesterol-lowering interventions
    Bucher, HC
    Griffith, LE
    Guyatt, GH
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (02) : 187 - 195
  • [10] Campeau L, 1997, NEW ENGL J MED, V336, P153